SL327 NEW
| Price | $31 | $40 | $64 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: SL327 | CAS No.: 305350-87-2 |
| Purity: 99.74% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | SL327 |
| Description | SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/0.22 μM; able to transport through the blood-brain barrier. |
| Kinase Assay | The ligand binding competition assays are performed. Cytosolic cell extracts from Hepa-1 cells are generated by the resuspension of the cell pellets in HEDG buffer [25 mM Hepes, 1 mM EDTA, 1 mM dithiothreitol, and 10% (v/v) glycerol, pH 7.5] containing 0.4 mM leupeptin, 4 mg/mL aprotinin, and 0.3 mM phenylmethylsulfonyl fluoride, homogenization, and centrifugation at 100,000 g for 45 min. Aliquots of the supernatant (120 μg) are incubated at room temperature for 2 h with the indicated concentrations of Pifithrin-α in the presence of 3 nM [3H]TCDD in HEDG buffer. After incubation on ice with hydroxyapatite for 30 min, HEDG buffer with 0.5% Tween 80 is added. The samples are centrifuged, washed twice, resuspended in 0.2 mL of scintillation fluid, and subjected to scintillation counting. Nonspecific binding is determined using a 150-fold molar excess of TCDF and subtracted from the total binding to obtain the specific binding. The specific binding is reported relative to [3H]TCDD alone[2]. |
| In vitro | Administration of 30 mg/kg of SL327 significantly impairs spatial learning and memory in mice. At a higher dose of 50 mg/kg, SL327 can cross the blood-brain barrier and inhibit conditioned fear by suppressing the phosphorylation of MAPK/ERK. |
| In vivo | SL327 does not inhibit a variety of other kinases, including PKA, PKC, or CamKII. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (149.1 mM), Sonication is recommended. Ethanol : 16.8 mg/mL (50 mM) |
| Keywords | Mitogen-activated protein kinase kinase | MEK | inhibit | SL327 | Inhibitor | MAPKK | MAP2K |
| Inhibitors Related | Rifampicin | 5-Fluorouracil | Ribavirin | Guanidine hydrochloride | 2,4-D | Resveratrol | Azelaic acid | Lidocaine hydrochloride | Acyclovir | Thymidine | Temozolomide | Folic acid |
| Related Compound Libraries | Highly Selective Inhibitor Library | Pain-Related Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Autophagy Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-20 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY